AdaptHealth Corp. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
AdaptHealth agreed to sell its Diabetes Health business to an undisclosed buyer for $235 million in cash (23.5% of current market cap), effective immediately as discontinued operations. Simultaneously, the company slashed full-year 2026 Adjusted EBITDA guidance from $680–730 million to $490–520 million (a $190–210 million reduction, or 28–30%), citing $100M from the divestiture, $55M from West Coast capitated contract strain, $30M from manufacturer price increases, and $15M from other portfolio actions. Q2 organic revenue grew 15.9% to $740.3M, but a $144.2M goodwill impairment drove net loss of $145.3M. Free cash flow YTD turned negative at -$48.4M vs. +$73.3M prior year.
Why this rating
Major portfolio reshaping (23.5% asset sale) and severe guidance cut (28–30% EBITDA reduction) material to $1B company, though underlying organic growth healthy. Execution risk remains.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.